A brand new peptide-based nanotube remedy sneaks chemo into drug-resistant most cancers cells, offering a novel workaround to considered one of oncology’s hardest hurdles.
CiQUS researchers have developed a novel molecular technique that permits a chemotherapy drug to enter the nucleus of tumor cells and exert its therapeutic influence, even in drug-resistant cancers. Their findings have been printed in ACS Utilized Supplies and Interfaces.
The research targeted on doxorubicin, a generally used chemotherapy drug. Extended remedy with this drug regularly ends in the formation of resistant cells, which causes substantial difficulties in medical use that the brand new method efficiently addresses, whereas sustaining the drug’s antitumor efficacy.
The method is predicated on a easy however highly effective idea: cyclic peptides (small amino acid rings) can stack and self-assemble into hole cylindrical constructions (nanotubes) on the floor of most cancers cell membranes.
The molecular-scale drug supply, created by a group led by Juan R. Granja, binds doxorubicin to those peptides and transports it to the cell nucleus through a mechanism that bypasses frequent drug resistance pathways, corresponding to efflux pumps. This allows the drug to avoid the mobile resistance mechanisms that usually render it ineffective.
Most cancers cell membranes include extra negatively charged lipids than wholesome cells. The cyclic peptides used on this research have a excessive affinity for these anionic surfaces, facilitating their interplay with tumor cells. Consequently, the peptide-drug conjugates enter resistant cells and go to the nucleus, the place doxorubicin intercalates with DNA to provide its cytotoxic influence.
Critically, the efficacy of this supply technique is determined by the construction of the cyclic peptide, significantly the inclusion of hydrophobic alkyl chains of particular lengths. Experimental analysis indicated that the chemical construction of the cyclic peptide is important for the creation of secure nanotubes, which improves their capability to penetrate malignant cells.
Drug resistance stays some of the vital challenges in most cancers remedy. Many tumors evolve programs to actively evade medicine, considerably decreasing the efficacy of present therapies. On this state of affairs, cyclic peptides function multifunctional supply autos, each enhancing uptake and shielding the drug from untimely expulsion from tumor cells, permitting doxorubicin to enter cells that may in any other case reject it.
This system, which mixes selectivity, efficient transport, and managed drug launch, opens the door to novel mixture chemotherapies by which peptide-based nanotechnology may be a potent ally in opposition to most cancers. Laboratory research confirmed that variations of the peptide with ten carbon alkyl tails have been the best, each in penetrating drug-resistant ovarian most cancers cells and delivering doxorubicin to the nucleus.
The scientists anticipate that this technique might spur the event of novel remedy strategies for difficult-to-treat tumors.
Journal Reference:
Vilela-Picos, M. et.al. (2025). Self-Assembling Cyclic Peptide Nanotubes for the Supply of Doxorubicin into Drug-Resistant Most cancers Cells. ACS Utilized Supplies and Interfaces. doi.org/10.1021/acsami.5c05264.
